|
Agnosia for Pain
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Whereas it is known that individuals lacking CYP2D6 activity (poor metabolizers, PM) suffer from poor analgesia from codeine, ultra-fast metabolizers (UM) due to the CYP2D6 gene duplication may experience exaggerated and even potentially dangerous opioidergic effects and no systematical study has been performed so far on this question.
|
16819548 |
2007 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
Inducing brain CYP2D with nicotine did not alter acute morphine analgesia (1.03-fold; p>0.8), or the rate of morphine tolerance (8.1%/day versus 7.6%; p>0.9).
|
28837793 |
2017 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
These cases demonstrate that analgesia with codeine or other opioids that use the CYP2D6 pathway after adenotonsillectomy may not be safe in young children with obstructive sleep apnea syndrome.
|
22492761 |
2012 |
|
Agnosia for Pain
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to investigate whether CYP2D6 poor metabolizers (PMs) yield the same analgesia post-operatively from intravenous oxycodone as extensive metabolizers (EMs).
|
19719813 |
2010 |
|
Agnosia for Pain
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Tramadol labeling indicates cytochrome P450 (CYP) isozyme 2D6 ultrarapid metabolizer can produce dangerous (+)-M1 levels, and CYP2D6 poor metabolizers insufficient (+)-M1 for analgesia.
|
31005596 |
2019 |
|
Agnosia for Pain
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to evaluate whether the different CYP2D6*10 genotypes have an effect on the postoperative tramadol analgesia in the Chinese population after elective nephrectomy.
|
25948472 |
2015 |
|
Alcohol Use Disorder
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
This study demonstrated the lower efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorders with <i>GA</i> genotype in <i>CYP2D6 1846G>A</i> polymorphic marker.
|
29988737 |
2018 |
|
Alcohol Use Disorder
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Effects of CYP2D6 activity on the efficacy and safety of mirtazapine in patients with depressive disorders and comorbid alcohol use disorder.
|
31100205 |
2019 |
|
Alzheimer Disease, Early Onset
|
0.300 |
Biomarker
|
disease |
CTD_human |
The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease.
|
7574463 |
1995 |
|
Alzheimer disease, familial, type 3
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
AD patients with mutant allele (*10) in CYP2D6 gene may respond better to donepezil than those with wild allele (*1).
|
22986607 |
2013 |
|
Alzheimer Disease, Late Onset
|
0.300 |
Biomarker
|
disease |
CTD_human |
The CYP2D6B allele is associated with a milder synaptic pathology in Alzheimer's disease.
|
7574463 |
1995 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
With respect to CYP2D6*4 polymorphism, significantly increased risk of AD was found in allelic contrast model of A vs. G (OR=1.29, 95%CI=1.03-1.62, P=0.026), co-dominant genetic model AA vs. GG (OR=1.91, 95%CI=1.04-3.51, P=0.038); and recessive genetic model AA vs. AG+GG (OR=1.88, 95%CI=1.03-3.46, P=0.041) in the overall populations.
|
24909950 |
2014 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study explored the influence of apolipoprotein E3 and CYP2D6 (rs1065852) gene polymorphisms on therapeutic responses to donepezil in Han Chinese patients with Alzheimer's disease.
|
26768225 |
2016 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We genotyped 86 subjects with diagnoses of probable AD to determine if they carried the alpha-1-antichymotrypsin (ACT) A allele, which has been associated with AD, or the CYP2D6 B mutant, found at increased frequency in the Lewy body variant (LBV) of AD.
|
8916107 |
1996 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
In AD patients treated with a multifactorial therapy, including cholinesterase inhibitors (e.g., donepezil), the best responders are the CYP2D6-related EMs and IMs, and the worst responders are PMs and UMs.
|
17908053 |
2007 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
About 57.76% of patients with Alzheimer's disease are extensive metabolisers (EMs) for CYP2D6 enzymes, 31.06% are intermediate metabolisers (IMs), 5.28% are poor metabolisers (PMs), and 5.90% are ultrarapid metabolisers (UMs); 73.71% are CYP2C19-EMs, 25.12% IMs, and 1.16% PMs; 60.87% are CYP2C9-EMs, 34.16% IMs, and 4.97% PMs; 82.75% are CYP3A4/5-EMs, 15.88% IMs, and 1.37% UMs.
|
20197699 |
2010 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Both univariate and multiple linear regression analysis indicated that only <i>CYP2D6*10</i> allele was associated with higher Cpss (<i>p</i>-value =0.029 and B =0.478, <i>p</i>-value =0.032, respectively) that might influence the clinical outcomes of donepezil. ie, TMSE (<i>p</i>-value =0.010 and B =4.527, <i>p</i>-value =0.001) and ΔTMSE (<i>p</i>-value =0.023 and B =4.107, <i>p</i>-value =0.002), especially in patients with AD.
|
31564952 |
2019 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Also, due to such a rare occurrence of the CYP2D6*4 polymorphism, we can not confirm the protective role of the polymorphism against AD in the Korean population.
|
11442888 |
2001 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The AD susceptibility gene cholesterol 25-hydroxylase (<i>CH25H</i>) is upregulated in the AD brain and is involved in the antiviral immune response.
|
29559905 |
2018 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
AD patients with mutant allele (*10) in CYP2D6 gene may respond better to donepezil than those with wild allele (*1).
|
22986607 |
2013 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
This study evaluated CYP2D6 polymorphisms to elucidate the stereoselective metabolism of donepezil and to confirm the association between the steady-state plasma concentrations of the pharmaco-effective S-donepezil and the therapeutic responses of Han Chinese patients with Alzheimer's disease.
|
26603528 |
2015 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The analysis of CYP2D6 genotypes may be useful in identifying subgroups of patients with AD who have different clinical responses to donepezil.
|
19738170 |
2009 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Cholesterol 25-hydroxylase on chromosome 10q is a susceptibility gene for sporadic Alzheimer's disease.
|
16909003 |
2005 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we compared frequencies of CYP2D6*3, *4, and *10 mutant alleles in 17 Japanese DLB patients to those among Alzheimer-type dementia (ATD) patients and healthy controls.
|
11285084 |
2001 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The aim of the study was to examine the genetic polymorphism in cytochrome P450 2D6 (CYP2D6) and glutathione S-transferases pi 1 (GSTP1) with respect to organochlorine pesticides (OCPs) and metals in AD.
|
24584466 |
2014 |